hormonotherapy

hormonotherapy

 [hor-mo″no-ther´ah-pe]
treatment by the use of hormones; endocrinotherapy.

hor·mo·no·ther·a·py

(hōr'mō-nō-thār'ă-pē),
Treatment with hormones.

hormonotherapy

(hor?mo-no-ther'a-pe)
The therapeutic use of hormones.
Synonym: cytotherapy (1); endocrinotherapy; glandular therapy; organotherapy.

hormonotherapy

treatment by the use of hormones; endocrinotherapy.
References in periodicals archive ?
11] All patients met the criteria as follows: regular menstruation (25-32 days), no hormonotherapy for at least 6 months, and histopathology confirmation.
Treatment includes a combination of surgery, hormonotherapy, radiation therapy, and chemotherapy that may be effective for the cure of localized disease; but there is no effective treatment strategy for metastasis, thus prostate cancer remains painful and often incurable.
For example, luminal A cancers require hormonotherapy whereas triple negative tumors respond better to chemotherapy (3).
The therapeutic approach to this type of cancer consists of local interventions (surgery and radiotherapy) and systemic interventions (chemotherapy, hormonotherapy and biological therapy) and can be employed in an isolated or concomitant manner (Majewski, Lopes, Davoglio, & Leite, 2012).
0]), ER+/PgR+ (45-50%/60-65%), CerbB2+ <10%, Ki67+ 30-35%, invasive carcinoma NST affecting the right breast, diagnosed 3 years prior to presentation, for which she underwent a multimodality treatment comprising breast removal surgery and axillary dissection--(Madden's modified radical mastectomy), followed by radio-, chemo- and hormonotherapy protocols.
Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for biological relapse (BR) after radical prostatectomy (RP): Results of the GETUG-AFU 16 phase III randomized trial--NCT00423475.
The incidence and the severity of the side effects associated with radiotherapy depend on dose, dose rate, the volume irradiated, the quality of radiation administered, age, gender, accompanying diseases, hormonotherapy, anemia and collagen vascular diseases.
Complementary chemotherapy or radiotherapy was administered, sometimes with hormonotherapy.
In contrast, adjuvant treatment was administered to 1658 patients, with chemotherapy alone in 515 (25%) and hormonotherapy in 554 (26.
Patient and tumor characteristics Characteristics n (%) Number of patients 69 (100) Median age 52 (range: 29-76) Performance status (ECOG) 0 6 (8) 1 50 (73) 2 13 (19) Hormone receptor status Positive 34 (49) Negative 30 (44) Unknown 5 (7) c-erbB-2 Positive 3+ 23 (34) IHC 2+, FISH+ 5 (7) Negative IHC 0/1+ 27 (39) IHC 2+, FISH- 10 (14) Unknown 4 (6) p53 High expression ([greater than or equal to]10) 8 (12) Low expression (<10) 41 (59) Unknown 20 (29) Visceral metastasis Present 52 (75) Absent 17 (25) Prior adjuvant treatments Chemotherapy 52 (75) Hormonotherapy 31 (45) Radiotherapy 34 (49) ECOG, Eastern Cooperative Oncology Group; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization.
Hormonotherapy was prescribed for 40,9 % of the patients.
In many cases, the grade determines the type of treatment: "grade-3" tumors require chemotherapy, while "grade-1" tumors are treated only with hormonotherapy.